---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-052704"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:57:26.850501+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics granted Nasdaq listing extension to Sept 16, 2025

## Summary
- Nasdaq Hearings Panel extended compliance deadline for MVLS Rule (minimum $35M market value for 10 consecutive days) to September 16, 2025.
- Extension is subject to BioXcel meeting certain interim conditions set by the Panel.
- Company previously faced potential delisting for failing to satisfy Nasdaq Listing Rule 5550(b)(2).
- Decision follows review of BioXcel's compliance plan and strategies for long-term compliance.

## SEC filing metadata
- accession: 0001104659-25-052704
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925052704/0001104659-25-052704-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925052704/tm2516117d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-052704
- JSON: https://secwatch.observer/filing/0001104659-25-052704.json
- Plain text: https://secwatch.observer/filing/0001104659-25-052704.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.